Ceftriaxone compared with cefotaxime for serious bacterial infections
- PMID: 2668428
- DOI: 10.1093/infdis/160.3.442
Ceftriaxone compared with cefotaxime for serious bacterial infections
Abstract
Ceftriaxone was compared with cefotaxime for the treatment of serious bacterial infections in a prospective, randomized, double-blind clinical trial. The dose of ceftriaxone was 2 g once a day, and the dose of cefotaxime was 2 g every 4 h. Metronidazole was added if anaerobic infection was suspected. Explicit criteria were used to define infections, clinical response, and adverse effects. Ceftriaxone was given to 88 patients and cefotaxime to 83. The two treatment groups did not differ in types of infection, infecting organisms, and severity of underlying disease. The response rate was 81% (71/88) for ceftriaxone and 80% (66/83) for cefotaxime. The power of the study to detect a 15% difference in response rate at P less than .1 was 90%. The frequency of diarrhea, thrombophlebitis, prothrombin time, prolongation, colonization, and superinfection did not differ between treatment groups. Ceftriaxone 2 g once a day was as safe and effective as cefotaxime 2 g every 4 h for suspected serious bacterial infections.
Similar articles
-
Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study.J Infect Dis. 1989 Sep;160(3):433-41. doi: 10.1093/infdis/160.3.433. J Infect Dis. 1989. PMID: 2668427 Clinical Trial.
-
Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections.Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):155-7. doi: 10.1016/0732-8893(95)00080-t. Diagn Microbiol Infect Dis. 1995. PMID: 7587031 Clinical Trial.
-
Treatment of lower respiratory tract infections with ceftriaxone and cefotaxime. A comparative study.Respiration. 1986;49(3):222-30. doi: 10.1159/000194882. Respiration. 1986. PMID: 3515468 Clinical Trial.
-
Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.Pharmacoeconomics. 1998 Jan;13(1 Pt 1):91-106. doi: 10.2165/00019053-199813010-00009. Pharmacoeconomics. 1998. PMID: 10175990 Review.
-
Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.Drugs. 1984 Jun;27(6):469-527. doi: 10.2165/00003495-198427060-00001. Drugs. 1984. PMID: 6329638 Review.
Cited by
-
Cefotaxime Versus Ceftriaxone: A Comprehensive Comparative Review.Cureus. 2024 Sep 11;16(9):e69146. doi: 10.7759/cureus.69146. eCollection 2024 Sep. Cureus. 2024. PMID: 39398799 Free PMC article. Review.
-
Cefotaxime-, Ciprofloxacin-, and Extensively Drug-Resistant Escherichia coli O157:H7 and O55:H7 in Camel Meat.Foods. 2023 Mar 29;12(7):1443. doi: 10.3390/foods12071443. Foods. 2023. PMID: 37048264 Free PMC article.
-
Impact of dosage schedule of antibiotics on the treatment of serious infections.Intensive Care Med. 1990;16 Suppl 3:S229-34. doi: 10.1007/BF01709706. Intensive Care Med. 1990. PMID: 2289996 Review.
-
Adverse effects of newer cephalosporins. An update.Drug Saf. 1993 Aug;9(2):132-42. doi: 10.2165/00002018-199309020-00005. Drug Saf. 1993. PMID: 8397890 Review.
-
Deep cervical abscesses in children: efficacy of the cefotaxime-rifampicin combination.Eur J Pediatr. 2023 May;182(5):2315-2324. doi: 10.1007/s00431-023-04917-1. Epub 2023 Mar 7. Eur J Pediatr. 2023. PMID: 36881146
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical